Zeaxanthin
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Zeaxanthin
- Accession Number
- DB11176
- Description
Zeaxanthin is a most common carotenoid alcohols found in nature that is involved in the xanthophyll cycle. As a coexistent isomer of lutein, zeaxanthin is synthesized in plants and some micro-organisms. It gives the distinct yellow color to many vegetables and other plants including paprika, corn, saffron and wolfberries. Zeaxanthin is one of the two primary xanthophyll carotenoids contained within the retina of the eye and plays a predominant component in the central macula. It is available as a dietary supplement for eye health benefits and potential prevention of age-related macular degeneration. Zeaxanthin is also added as a food dye.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Zeaxanthin (DB11176)
- Weight
- Average: 568.886
Monoisotopic: 568.428031043 - Chemical Formula
- C40H56O2
- Synonyms
- Not Available
- External IDs
- E 161H
- E-161H(I)
- INS NO.161H(I)
- INS-161H(I)
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
- Not Available
- Associated Therapies
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Take with or without food.
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image VISOCAP ® Zeaxanthin (2 mg) + Cupric sulfate (2 mg) + DL-alpha tocopheryl acetate (50 IU) + Lutein (2 mg) + Manganese (5 mg) + Riboflavin (5 mg) + Selenium (0.2 mg) + Sodium ascorbate (200 mg) + Vitamin A (3300 IU) + Zinc sulfate monohydrate (24 mg) Capsule, liquid filled Oral 2006-11-10 Not applicable Colombia 
Vista Advanced AREDS2 Formula Zeaxanthin (1 mg/966.47mg) + Ascorbic acid (250 mg/966.47mg) + Copper gluconate (1 mg/966.47mg) + Glutathione (25 mg/966.47mg) + Lutein (5 mg/966.47mg) + Selenium (0.0275 mg/966.47mg) + Vitamin E (137.5 mg/966.47mg) Capsule Oral Red Wedding LLC 2020-09-01 Not applicable US 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Macuvex Zeaxanthin (1 mg/1) + Ascorbic acid (250 mg/1) + Copper (1 mg/1) + Folic acid (1 mg/1) + Lutein (5 mg/1) + Zinc oxide (40 mg/1) + alpha-Tocopherol acetate (200 [iU]/1) Capsule Oral Sterling-knight Pharmaceuticals,LLC 2014-11-16 2015-07-28 US Macuzin Zeaxanthin (2 mg/1) + Ascorbic acid (500 mg/1) + Copper (2 mg/1) + DL-alpha tocopheryl acetate (400 [iU]/1) + Folic acid (1 mg/1) + Lutein (10 mg/1) + Zinc oxide (80 mg/1) Capsule Oral Sterling-Knight Pharmaceuticals, LLC 2015-04-30 2018-07-30 US Ocuvel Zeaxanthin (2 mg/1) + Ascorbic acid (500 mg/1) + Copper (2 mg/1) + Folic acid (1 mg/1) + Lutein (10 mg/1) + Zinc oxide (80 mg/1) + alpha-Tocopherol acetate (400 [iU]/1) Capsule Oral Adler-Stern Pharmaceuticals, LLC 2014-11-05 Not applicable US Ocuvel Zeaxanthin (1 mg/1) + Ascorbic acid (250 mg/1) + Copper (1 mg/1) + Folic acid (0.5 mg/1) + Lutein (5 mg/1) + Zinc oxide (40 mg/1) + alpha-Tocopherol acetate (200 [iU]/1) Capsule Oral Adler-Stern Pharmaceuticals, LLC 2014-12-01 Not applicable US Tozal Zeaxanthin (3 mg/31) + Ascorbic acid (452 mg/31) + Cholecalciferol (1000 [iU]/31) + Copper (1.6 mg/31) + Cyanocobalamin (100 ug/31) + Folic acid (1 mg/31) + Lutein (15 mg/31) + Omega-3 fatty acids (600 mg/31) + Pyridoxine hydrochloride (20 mg/31) + Taurine (400 mg/31) + Vitamin A palmitate (10000 [iU]/31) + Vitamin E (200 [iU]/31) + Zinc picolinate (40 mg/31) Capsule, gelatin coated Oral Focus Laboratories, Inc. 2013-06-01 2015-07-15 US Vista Advanced AREDS2 Formula Zeaxanthin (1 mg/966.47mg) + Ascorbic acid (250 mg/966.47mg) + Copper gluconate (1 mg/966.47mg) + Glutathione (25 mg/966.47mg) + Lutein (5 mg/966.47mg) + Selenium (0.0275 mg/966.47mg) + Vitamin E (137.5 mg/966.47mg) Capsule Oral Red Wedding LLC 2020-09-01 Not applicable US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as xanthophylls. These are carotenoids containing an oxygenated carotene backbone. Carotenes are characterized by the presence of two end-groups (mostly cyclohexene rings, but also cyclopentene rings or acyclic groups) linked by a long branched alkyl chain. Carotenes belonging form a subgroup of the carotenoids family. Xanthophylls arise by oxygenation of the carotene backbone.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Tetraterpenoids
- Direct Parent
- Xanthophylls
- Alternative Parents
- Secondary alcohols / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic homomonocyclic compound / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Secondary alcohol / Xanthophyll
- Molecular Framework
- Aliphatic homomonocyclic compounds
- External Descriptors
- carotenol (CHEBI:27547) / C40 isoprenoids (tetraterpenes), Carotenoids (C06098) / C40 isoprenoids (tetraterpenes) (LMPR01070261)
Chemical Identifiers
- UNII
- CV0IB81ORO
- CAS number
- 144-68-3
- InChI Key
- JKQXZKUSFCKOGQ-QAYBQHTQSA-N
- InChI
- InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-24,35-36,41-42H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36-/m1/s1
- IUPAC Name
- (1R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-3,5,5-trimethylcyclohex-3-en-1-ol
- SMILES
- C\C(\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0002789
- KEGG Compound
- C06098
- PubChem Compound
- 5280899
- PubChem Substance
- 347827933
- ChemSpider
- 4444421
- 39918
- ChEBI
- 27547
- ChEMBL
- CHEMBL2359248
- ZINC
- ZINC000008220175
- Wikipedia
- Zeaxanthin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Age-Related Macular Degeneration (ARMD) / Cataracts 1 2 Completed Treatment NPDR - Non Proliferative Diabetic Retinopathy / Type 2 Diabetes Mellitus 1 2 Recruiting Prevention Nutrient Deficiency / Pregnancy Related 1 1, 2 Recruiting Other Glaucoma 1 1, 2 Unknown Status Treatment Age-Related Macular Degeneration (ARMD) 1 Not Available Completed Not Available Idiopathic Juxtafoveal Telangiectasia 1 Not Available Completed Supportive Care Age Related Macular Degeneration (ARMD) / Age-Related Macular Degeneration (ARMD) / Cognition Disorders 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral Capsule, gelatin coated Oral Tablet Oral Capsule, liquid filled Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000649 mg/mL ALOGPS logP 8.3 ALOGPS logP 8.35 ChemAxon logS -5.9 ALOGPS pKa (Strongest Acidic) 18.91 ChemAxon pKa (Strongest Basic) -0.79 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 40.46 Å2 ChemAxon Rotatable Bond Count 10 ChemAxon Refractivity 194.95 m3·mol-1 ChemAxon Polarizability 73.47 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on December 03, 2015 16:51 / Updated on June 12, 2020 16:53